health
Engineered regulatory T cells reduced lupus signs in two mouse models
A bioRxiv preprint reports that CD19-targeted engineered regulatory T cells persisted for more than four months and reduced several measures of lupus in two mouse models. The findings are preclinical, not results from patients.